Archives

CREATE Medicines Doses First Patient in Phase 1/2 Study of MT-304, a First-in-Class Multi-immune In Vivo CAR Therapy Targeting HER2-Positive Solid Tumors

B Validates platform’s ability to rapidly iterate across immune cell types Leverages novel NK and myeloid co-programming architecture to deliver coordinated immune activation Powered by… Login to continue reading Login…

Read MoreCREATE Medicines Doses First Patient in Phase 1/2 Study of MT-304, a First-in-Class Multi-immune In Vivo CAR Therapy Targeting HER2-Positive Solid Tumors

ZeroEyes and High Tech High Collaboration Protects Students While Maintaining Open, Collaborative Learning Atmosphere

B Project-Based Charter School Network Demonstrates Commitment to Safety While Preserving Open, Relationship-Driven Culture PHILADELPHIA, April 23, 2026 /PRNewswire/ — ZeroEyes, creators of the leading AI-powered… Login to continue reading Login…

Read MoreZeroEyes and High Tech High Collaboration Protects Students While Maintaining Open, Collaborative Learning Atmosphere